Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Kenporen Proposes Excluding OTC-Like Pollinosis Drugs from Health Coverage, Expecting Annual Savings of 60 Billion Yen
August 26, 2019
-
REGULATORY Japan to Set Up Dedicated Team to Expedite Review of Sakigake-Designated Cell/Gene Therapies
August 23, 2019
-
REGULATORY Tecentriq Wins Japan Nod for SCLC as 1st Checkpoint Drug for This Use
August 23, 2019
-
BUSINESS Price Revision Rates in October Re-Pricing Vary in Crowded DPP-4 Class: Survey
August 22, 2019
-
BUSINESS Frontloaded Price Cuts before Regular April Revision Hurts, Say Drug Makers
August 21, 2019
-
REGULATORY No PMP for Tecentriq, but Prices Rise for All 5 Checkpoint Drugs in Tax Hike Re-Pricing
August 21, 2019
-
BUSINESS Tax Hike Re-Pricing Slams Small Pharma and Gx Players, Impact Milder for Big Firms: Survey
August 20, 2019
-
REGULATORY Kymriah, All Checkpoint Drugs but Tecentriq to Get Price Maintenance Premium in October Re-Pricing
August 20, 2019
-
BUSINESS Sumitomo Dainippon Flip-Plops on Sales Force Cutback as It Ramps Up Diabetes Push
August 19, 2019
-
REGULATORY First “Post-Nesp” Renal Anemia Med Could Land Japan Approval in September
August 16, 2019
-
REGULATORY Japan OKs Zetia Generic, Possibly AG, towards December Listing; No Entry for Lyrica This Time
August 16, 2019
-
TRENDS Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
-
BUSINESS Sumitomo Dainippon Going Full Tilt for Napabucasin Colorectal Cancer Trial after Pancreatic Flop
August 8, 2019
-
BUSINESS Novartis’ Entresto Filed in Japan for Chronic Heart Failure
August 7, 2019
-
BUSINESS Gearing Up for Japan Debut, Daiichi Sankyo Mounting Push for AML Med Vanflyta
August 6, 2019
-
REGULATORY MHLW Pharma Bureau Chief Keen on Early Enactment of PMD Amendment Bill
August 5, 2019
-
REGULATORY Tecentriq’s SCLC Use Gets MHLW Panel Nod for September Approval
August 5, 2019
-
REGULATORY MHLW Finalizing Timing to Announce Post-Oct. 1 NHI Prices, Bureau Chief Hints at August Possibility
August 2, 2019
-
BUSINESS Takeda Squeezes Projected Losses for FY2019 as Velcade Copy Lags
August 1, 2019
-
BUSINESS Crushing Defeat or Sign of Hope? Analyst, KOL Give Mixed Views for CheckMate-227
July 31, 2019
ページ
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…